Moleculin Biotech Completes Enrollment for Pivotal MIRACLE Trial Interim Data Readout, Setting Stage for Mid-2026 Unblinding
MBRX sits 17% above its 52-week low of $1.79.
Summary
Moleculin Biotech announced the completion of enrollment for the 45-subject interim analysis in its pivotal MIRACLE trial, triggering the countdown to a critical data unblinding in mid-2026.
Key Events · Product Development and Regulatory · MBRX
-
Pivotal Trial Enrollment Milestone Achieved
The company announced the enrollment of the 45th subject in its Phase 2B/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (R/R AML).
-
Interim Data Unblinding On Track
This enrollment milestone triggers the final phase of preparation for the interim 45-subject data unblinding, which remains on track for mid-2026.
-
Critical Inflection Point for Company
The company views this upcoming data readout as a 'potentially defining inflection point' and the 'most important milestone in our history to date,' especially given its recent going concern warning.
-
Follows Encouraging Preliminary Data
This progress follows the preliminary blinded composite complete remission rate of 40% reported in February 2026 for the first 30 patients in the trial.
Analysis · MBRX · Life Sciences
Moleculin Biotech, a clinical-stage company facing a going concern warning and short cash runway, has achieved a critical operational milestone by enrolling the 45th subject in its pivotal Phase 2B/3 MIRACLE trial. This completion triggers the final preparations for the highly anticipated interim data unblinding, expected in mid-2026. This event is particularly significant as the company previously reported encouraging preliminary blinded data for 30 patients, showing a 40% composite complete remission rate. The upcoming unblinding represents a potentially defining inflection point for the company and its lead drug candidate, Annamycin, in the treatment of relapsed or refractory acute myeloid leukemia (R/R AML).
At the time of this filing, MBRX was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11M. The 52-week trading range was $1.79 to $33.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.